Is There a Need for Tandem Transplants in Today's Myeloma?
Myeloma specialist, Dr. David Vesole tackles a pressing question in myeloma research: what's the role of tandem transplants in today's myeloma? A tandem autologous transplant means that two autologous transplants are performed within six months of each other and have often been used in the past for those with high-risk multiple myeloma. But considering all of the new immunotherapies being approved, does tandem transplant still have a place in the myeloma arsenal? Find out with us on May 10th.
Audrey introduces the agenda of the event and featured speaker Dr. David Vesole.
Dr. David Vesole talks about tandem transplant in Myeloma
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Dr. David Vesole
David H. Vesole is director of the Myeloma Program at MedStar Georgetown University Hospital and a professor of Medicine at Georgetown University. Concurrently, he is co-director of the Myeloma Division and director of Myeloma Research at the John Theurer Cancer Center at Hackensack University Medical Center. Previously, Dr. Vesole was director of the BMT Program at Loyola University in Maywood, IL, an attending physician at St. Vincent's Comprehensive Cancer Center in New York, and Professor of Medicine and Clinical Director of the Blood and Marrow Transplant Program at the Medical College of Wisconsin in Milwaukee.